Shanghai Zerun Biotechnology
Shanghai Zerun Biotechnology Co. Ltd. is a Chinese biotechnology company based in Shanghai, China. It operates as a subsidiary of Walvax Biotechnology.
Activities
Research and development
The company has received three grants from the Bill & Melinda Gates Foundation.
- September 2015: $5,003,336 to improve women's access to low-cost bivalent HPV vaccine in GAVI-supported countries1)
- October 2019: $2,505,923 to improve women's access to low-cost nonavalent HPV vaccine in GAVI-supported countries2)
In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants.4) As of October 2022, CEPI had provided up to $25.1 million USD towards a candidate called 202-CoV, but had ceased further funding.5) The chimeric protein candidate remains in Phase I clinical trials.